Receptor for advanced glycation end-products expression in subcutaneous adipose tissue is related to coronary artery disease

European Journal of Endocrinology

Volumn 164, Issue 4, 2011, Pages 529-537

  Rodino Janeiro B K ^a,b   Salgado Somoza, A ^a,b   Teijeira Fernandez E ^a,b   Gonzalez Juanatey J R ^a,b,c   Alvarez E ^a,c   Eiras, S ^a,b  

^a Instituto de Investigación Sanitaria de Santiago de Compostela IDIS   (Spain)

^b Pediatric Nutrition Research Group Health Research Institute of Santiago de Compostela   (Spain)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; BETA ACTIN; CATALASE; HEMOGLOBIN A1C; MESSENGER RNA; PROTEIN CYBA; PROTEIN P22; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 5; UNCLASSIFIED DRUG; CHOLESTEROL; LIPID; TRIACYLGLYCEROL;

ACTB GENE; AGED; ARTICLE; CAT GENE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYBA GENE; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; GENE; GENE EXPRESSION; GLYCEMIC CONTROL; HEART SURGERY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIPID ANALYSIS; MALE; NOX4 GENE; NOX5 GENE; NUCLEOTIDE SEQUENCE; OBESITY; P22 PHOX GENE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN MODIFICATION; RAGE GENE; SUBCUTANEOUS FAT; ADIPOSE TISSUE; BIOPSY; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; EPICARDIAL ADIPOSE TISSUE; LIPID BLOOD LEVEL; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING;

ADIPOSE TISSUE; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CATALASE; CORONARY ARTERY DISEASE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NADPH OXIDASE; REACTIVE OXYGEN SPECIES; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUBCUTANEOUS FAT;

EID: 79953204648     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0904     Document Type: Article

References (32)

1. Marques BG, Hausman DB & Martin RJ. Association of fat cell size and paracrine growth factors in development of hyperplastic obesity. American Journal of Physiology 1998 275 R1898-R1908.
2. Dixon JB. The effect of obesity on health outcomes. Molecular and Cellular Endocrinology 2010 316 104-108. (doi:10.1016/j.mce.2009.07.008)
3. Ahmadi N, Nabavi V, Yang E, Hajsadeghi F, Lakis M, Flores F, Zeb I, Bevinal M, Ebrahimi R&Budoff M. Increased epicardial, pericardial, and subcutaneous adipose tissue is associated with the presence and severity of coronary artery calcium. Academic Radiology 2010 17 1518-1524. (doi:10.1016/j.acra.2010.08.017)
4. Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, Vasan RS, Murabito JM, Meigs JB, Cupples LA, D'Agostino RB Sr & O'Donnell CJ. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007 116 39-48. (doi:10.1161/CIRCULATIONAHA.106.675355)
5. Wallner SJ, Horejsi R, Zweiker R, Watzinger N, Moller R, Schnedl WJ, Schauenstein K & Tafeit E. ROC analysis of subcutaneous adipose tissue topography (SAT-Top) in female coronary heart disease patients and healthy controls. Journal of Physiological Anthropology 2008 27 185-191. (doi:10.2114/jpa2.27.185)
6. Eiras S, Teijeira-Fernandez E, Salgado-Somoza A, Couso E, Garcia- Caballero T, Sierra J & Juanatey JR. Relationship between epicardial adipose tissue adipocyte size and MCP-1 expression. Cytokine 2010 51 207-212. (doi:10.1016/j.cyto.2010.05.009)
7. Kremen J, Dolinkova M, Krajickova J, Blaha J, Anderlova K, Lacinova Z, Haluzikova D, Bosanska L, Vokurka M, Svacina S & Haluzik M. Increased subcutaneous and epicardial adipose tissue production of proinflammatory cytokines in cardiac surgery patients: possible role in postoperative insulin resistance. Journal of Clinical Endocrinology and Metabolism 2006 91 4620-4627. (doi:10.1210/jc.2006-1044)
8. Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, Sarov-Blat L, O'Brien S, Keiper EA, Johnson AG, Martin J, Goldstein BJ & Shi Y. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 2003 108 2460-2466. (doi:10.1161/01.CIR.0000099542.57313.C5)
9. Eiras S, Teijeira-Fernandez E, Shamagian LG, Fernandez AL, Vazquez-Boquete A & Gonzalez-Juanatey JR. Extension of coronary artery disease is associated with increased IL-6 and decreased adiponectin gene expression in epicardial adipose tissue. Cytokine 2008 43 174-180. (doi:10.1016/j.cyto.2008.05.006)
10. Iglesias MJ, Eiras S, Pineiro R, Lopez-Otero D, Gallego R, Fernandez AL, Lago F & Gonzalez-Juanatey JR. Gender differences in adiponectin and leptin expression in epicardial and subcutaneous adipose tissue. Findings in patients undergoing cardiac surgery. Revista Española de Cardiología 2006 59 1252-1260. (doi:10.1157/13096596)
11. Teijeira-Fernandez E, Eiras S, Grigorian-Shamagian L, Fernandez A, Adrio B & Gonzalez-Juanatey JR. Epicardial adipose tissue expression of adiponectin is lower in patients with hypertension. Journal of Human Hypertension 2008 22 856-863. (doi:10.1038/jhh.2008.75)
12. Teijeira-Fernandez E, Eiras S, Grigorian-Shamagian L, Salgado- Somoza A, Martinez-Comendador JM & Gonzalez-Juanatey JR. Diabetic and nondiabetic patients express similar adipose tissue adiponectin and leptin levels. International Journal of Obesity 2010 34 1200-1208. (doi:10.1038/ijo.2010.30)
13. Ueno H, Koyama H, Shoji T, Monden M, Fukumoto S, Tanaka S, Otsuka Y, Mima Y, Morioka T, Mori K, Shioi A, Yamamoto H, Inaba M & Nishizawa Y. Receptor for advanced glycation end-products (RAGE) regulation of adiposity and adiponectin is associated with atherogenesis in apoE-deficient mouse. Atherosclerosis 2010 211 431-436. (doi:10.1016/j.atherosclerosis.2010.04.006)
14. Koyama H, Yamamoto H & Nishizawa Y. RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases. Molecular Medicine 2007 13 625-635. (doi:10.2119/2007-00087.Koyama)
15. Goldin A, Beckman JA, Schmidt AM & Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006 114 597-605. (doi:10.1161/CIRCULATIONAHA.106.621854)
16. Basta G, Schmidt AM & De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovascular Research 2004 63 582-592. (doi:10.1016/j.cardiores. 2004.05.001)
17. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, Kislinger T, Stern DM, Schmidt AM & De Caterina R. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002 105 816-822. (doi:10. 1161/hc0702.104183)
18. Yan SF, Ramasamy R & Schmidt AM. The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circulation Research 2010 106 842-853. (doi:10.1161/CIRCRESAHA.109.212217)
19. Brandes RP & Kreuzer J. Vascular NADPH oxidases: molecular mechanisms of activation. Cardiovascular Research 2005 65 16-27. (doi:10.1016/j.cardiores. 2004.08.007)
20. Taniyama Y & Griendling KK. Reactive oxygen species in the vasculature:molecular and cellularmechanisms.Hypertension 2003 42 1075-1081. (doi:10.1161/01.HYP.0000100443.09293.4F)
21. Salgado-Somoza A, Teijeira-Fernandez E, Fernandez AL, Gonzalez- Juanatey JR & Eiras S. Proteomic analysis of epicardial and subcutaneous adipose tissue reveals differences in proteins involved in oxidative stress. American Journal of Physiology. Heart and Circulatory Physiology 2010 299 H202-H209. (doi:10.1152/ajpheart.00120.2010)
22. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D & Schmidt AM. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999 97 889-901. (doi:10.1016/S0092-8674(00)80801-6)
23. Yan SF, Ramasamy R & Schmidt AM. The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. Expert Reviews in Molecular Medicine 2009 11 e9. (doi:10.1017/ S146239940900101X)
24. Gao J, Shao Y, Lai W, Ren H & Xu D. Association of polymorphisms in the RAGE gene with serum CRP levels and coronary artery disease in the Chinese Han population. Journal of Human Genetics 2010 55 668-675. (doi:10.1038/jhg. 2010.85)
25. Hofmann MA, Yang Q, Harja E, Kedia P, Gregersen PK, Cupples LA, Schmidt AM & Hudson BI. The RAGE Gly82Ser polymorphism is not associated with cardiovascular disease in the Framingham offspring study. Atherosclerosis 2005 182 301-305. (doi:10.1016/j.atherosclerosis.2005.02.006)
26. Yoon SJ, Park S, Shim CY, Park CM, Ko YG, Choi D, Park HY, Oh B, Kim H, Jang Y & Chung N. Association of RAGE gene polymorphisms with coronary artery disease in the Korean population. Coronary Artery Disease 2007 18 1-8. (doi:10.1097/ MCA.0b013e3280105b4d)
27. Park IH, Yeon SI, Youn JH, Choi JE, Sasaki N, Choi IH & Shin JS. Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. Molecular Immunology 2004 40 1203-1211. (doi:10.1016/j. molimm. 2003.11.027)
28. Lassegue B & Griendling KK. NADPH oxidases: functions and pathologies in the vasculature. Arteriosclerosis, Thrombosis, and Vascular Biology 2010 30 653-661. (doi:10.1161/ATVBAHA.108.181610)
29. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM & Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. American Journal of Physiology. Endocrinology and Metabolism 2001 280 E685-E694.
30. Gletsu-Miller N, Hansen JM, Jones DP, Go YM, Torres WE, Ziegler TR & Lin E. Loss of total and visceral adipose tissue mass predicts decreases in oxidative stress after weight-loss surgery. Obesity 2009 17 439-446. (doi:10.1038/oby.2008.542)
31. Jandeleit-Dahm K, Watson A & Soro-Paavonen A. The AGE/ RAGE axis in diabetes-accelerated atherosclerosis. Clinical and Experimental Pharmacology and Physiology 2008 35 329-334. (doi:10.1111/j.1440-1681.2007.04875.x)
32. Tan AL, Sourris KC, Harcourt BE, Thallas-Bonke V, Penfold S, Andrikopoulos S, Thomas MC, O'Brien RC, Bierhaus A, Cooper ME, Forbes JM & Coughlan MT. Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy. American Journal of Physiology. Renal Physiology 2010 298 F763-F770. (doi:10.1152/ajprenal.00591.2009)